Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | bromodomain adjacent to zinc finger domain, 2B | Starlite/ChEMBL | No references |
Homo sapiens | geminin, DNA replication inhibitor | Starlite/ChEMBL | No references |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Brugia malayi | Hypothetical 65.5 kDa Trp-Asp repeats containing protein F02E8.5 inchromosome X | geminin, DNA replication inhibitor | 209 aa | 176 aa | 27.8 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Loa Loa (eye worm) | hypothetical protein | 0.0046 | 0.1254 | 0.3541 |
Echinococcus multilocularis | bromodomain adjacent to zinc finger domain | 0.0043 | 0.1091 | 0.1091 |
Echinococcus granulosus | bromodomain adjacent to zinc finger domain | 0.0043 | 0.1091 | 0.1091 |
Schistosoma mansoni | acetyl-CoA C-acetyltransferase | 0.0027 | 0.0198 | 0.0198 |
Brugia malayi | Bromodomain containing protein | 0.0046 | 0.1249 | 0.2673 |
Loa Loa (eye worm) | hypothetical protein | 0.0049 | 0.1412 | 0.4014 |
Schistosoma mansoni | hypothetical protein | 0.0205 | 1 | 1 |
Echinococcus multilocularis | fetal alzheimer antigen, falz | 0.0027 | 0.0198 | 0.0198 |
Loa Loa (eye worm) | hypothetical protein | 0.0085 | 0.3413 | 1 |
Schistosoma mansoni | hypothetical protein | 0.0025 | 0.0071 | 0.0071 |
Schistosoma mansoni | hypothetical protein | 0.0205 | 1 | 1 |
Schistosoma mansoni | bromodomain containing protein | 0.0076 | 0.2916 | 0.2916 |
Echinococcus granulosus | bromodomain adjacent to zinc finger domain | 0.0072 | 0.2677 | 0.2677 |
Echinococcus multilocularis | bromodomain adjacent to zinc finger domain | 0.0072 | 0.2677 | 0.2677 |
Echinococcus granulosus | fetal alzheimer antigen falz | 0.0027 | 0.0198 | 0.0198 |
Brugia malayi | Bromodomain containing protein | 0.0091 | 0.3698 | 1 |
Echinococcus multilocularis | geminin | 0.0205 | 1 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0052 | 0.1539 | 0.4395 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Potency (functional) | 0.3264 uM | PubChem BioAssay. A quantitative high throughput screen for small molecules that induce DNA re-replication in SW480 colon adenocarcinoma cells. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 0.8913 uM | PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of BAZ2B. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID504391] | ChEMBL. | No reference |
Potency (functional) | 1.1689 uM | PUBCHEM_BIOASSAY: Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 48 hour incubation. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID488752, AID488774, AID504848, AID504850] | ChEMBL. | No reference |
Potency (functional) | 18.526 uM | PUBCHEM_BIOASSAY: Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 96 hour incubation. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID488745, AID488752, AID488774, AID504848, AID504850] | ChEMBL. | No reference |
Potency (functional) | 23.1093 uM | PubChem BioAssay. A quantitative high throughput screen for small molecules that induce DNA re-replication in MCF 10a normal breast cells. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 28.1838 uM | PUBCHEM_BIOASSAY: qHTS for Inhibitors of Polymerase Iota. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID588623] | ChEMBL. | No reference |
Species name | Source | Reference | Is orphan |
---|---|---|---|
Plasmodium falciparum | ChEMBL23 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.